Patents by Inventor Klaus Gjervig Jensen

Klaus Gjervig Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11130775
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 28, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fog Jacobsen
  • Patent number: 11110110
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • Patent number: 11059798
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: July 13, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Publication number: 20200392176
    Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
    Type: Application
    Filed: May 18, 2020
    Publication date: December 17, 2020
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fogh Jacobsen
  • Publication number: 20200338102
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 29, 2020
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • Patent number: 10729710
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: August 4, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • Publication number: 20200131143
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: November 4, 2019
    Publication date: April 30, 2020
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN
  • Patent number: 10501427
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 10, 2019
    Assignee: H. LUNDBECK A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Publication number: 20190160083
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Application
    Filed: November 23, 2018
    Publication date: May 30, 2019
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • Publication number: 20190031631
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN
  • Patent number: 10118907
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 6, 2018
    Assignee: H. LUNDBECK A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Publication number: 20170158650
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN
  • Patent number: 9617231
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: April 11, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Publication number: 20160068497
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 10, 2016
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN
  • Patent number: 9216961
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 22, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Publication number: 20150307458
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: March 13, 2015
    Publication date: October 29, 2015
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN
  • Patent number: 9012453
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: April 21, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
  • Patent number: 8575174
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: November 5, 2013
    Assignee: H. Lundbeck A/S
    Inventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen, Mette Graulund Hvenegaard, Lassina Badolo, Mikkel Fog Jacobsen
  • Publication number: 20130281436
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 24, 2013
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN, Mette Graulund HVENEGAARD, Lassina BADOLO, Mikkel Fog JACOBSEN
  • Publication number: 20120322811
    Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.
    Type: Application
    Filed: June 19, 2012
    Publication date: December 20, 2012
    Inventors: Morten JORGENSEN, Peter Hongaard ANDERSEN, Klaus Gjervig JENSEN, Mette Graulund HVENEGAARD, Lassina BADOLO, Mikkel Fog JACOBSEN